StockData
PRENasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as PRENW

Prenetics Global Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026
$19.02+0.50 (+2.70%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

Prenetics Global Ltd revenue by segment

By business segment

RevenueFY2025FY2024FY2023FY2022FY2021FY2020% of revenueYoY
Consumer Health$79.45M$5.57M––––86.0%+1326.6%
Prevention$12.95M$10.37M$6.16M$13.16M––14.0%+24.9%
Diagnostics–$14.69M$15.59M$0$0$50.91M––
Prevention––$6.16M$13.16M$12.53M$14.26M––

By product or service

RevenueFY2025FY2024FY2023FY2022FY2021FY2020% of revenueYoY
Consumer health - health and wellness solutions$60.15M$370.00K$0$0––65.1%+16156.5%
Consumer health - sports distribution$19.30M$5.20M$0$0––20.9%+271.1%
Prevention - genetic testing$12.95M$10.37M$6.16M$13.16M––14.0%+24.9%
Revenue from service$0$0$0$0$0$00.0%–
Diagnostics - Cancer Treatment [Member]–$14.69M$15.59M$0––––

By region

RevenueFY2025FY2024FY2023FY2022FY2021FY2020% of revenueYoY
United States$69.32M$5.51M$0$0––75.0%+1157.8%
Hong Kong SAR China$23.07M$10.43M$6.16M$13.16M$12.53M$35.41M25.0%+121.3%
United Kingdom–$2.78M$2.27M$0$0$29.77M––
Taiwan–$7.09M$9.33M$0$0–––
Rest of the world–$972.00K$1.18M$0$0–––

From the segment and revenue-disaggregation notes of Prenetics Global's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.